|
US6953668B1
(en)
|
1992-11-05 |
2005-10-11 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen
|
|
US7070782B1
(en)
*
|
1992-11-05 |
2006-07-04 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen
|
|
US7105159B1
(en)
*
|
1992-11-05 |
2006-09-12 |
Sloan-Kettering Institute For Cancer Research |
Antibodies to prostate-specific membrane antigen
|
|
US6569432B1
(en)
*
|
1995-02-24 |
2003-05-27 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen and uses thereof
|
|
ATE317435T1
(de)
|
1995-02-24 |
2006-02-15 |
Sloan Kettering Inst Cancer |
Prostataspezifisches membranes antigen und seine anwendungen
|
|
US5773292A
(en)
*
|
1995-06-05 |
1998-06-30 |
Cornell University |
Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood
|
|
US6379669B1
(en)
*
|
1995-08-04 |
2002-04-30 |
Akhouri A. Sinha |
Targeting of organs by immunoconjugates
|
|
US20040253246A1
(en)
*
|
1996-02-23 |
2004-12-16 |
Israeli Ron S. |
Prostate-specific membrane antigen and uses thereof
|
|
US7381407B1
(en)
*
|
1996-03-25 |
2008-06-03 |
Medarex, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
|
US6150508A
(en)
*
|
1996-03-25 |
2000-11-21 |
Northwest Biotherapeutics, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
|
US6962981B1
(en)
|
1996-03-25 |
2005-11-08 |
Medarex, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
|
US6107090A
(en)
|
1996-05-06 |
2000-08-22 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
|
|
US6207805B1
(en)
*
|
1997-07-18 |
2001-03-27 |
University Of Iowa Research Foundation |
Prostate cell surface antigen-specific antibodies
|
|
AU9233698A
(en)
*
|
1997-11-22 |
1999-06-17 |
Robert A. Levine |
Method for the detection, identification, enumeration and confirmation of circulating cancer cells and/or hematologic progenitor cells in whole blood
|
|
US6881405B2
(en)
|
1998-06-15 |
2005-04-19 |
Altarex Medical Corp. |
Reagents and methods for inducing an immune response to prostate specific antigen
|
|
EP1150701A4
(en)
*
|
1999-01-22 |
2003-03-26 |
Burnham Inst |
TARGETING PRO-APOPTOTIC CONJUGATES AND METHODS FOR USE THEREOF
|
|
CA2360073C
(en)
|
1999-01-28 |
2011-01-18 |
Gen-Probe Incorporated |
Probes and primers for detecting prostate specific antigen (psa) in a biological sample
|
|
US6167297A
(en)
*
|
1999-05-05 |
2000-12-26 |
Benaron; David A. |
Detecting, localizing, and targeting internal sites in vivo using optical contrast agents
|
|
US6278726B1
(en)
*
|
1999-09-10 |
2001-08-21 |
Interdigital Technology Corporation |
Interference cancellation in a spread spectrum communication system
|
|
ATE553131T1
(de)
*
|
2000-05-08 |
2012-04-15 |
Celldex Res Corp |
Humane monoklonale antikörper gegen dendritische zellen
|
|
EP2277542B1
(en)
|
2001-06-01 |
2014-04-16 |
Cornell Research Foundation Inc. |
Modified antibodies to prostrate-specific membrane antigen and uses thereof
|
|
US7514078B2
(en)
*
|
2001-06-01 |
2009-04-07 |
Cornell Research Foundation, Inc. |
Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
|
|
IL159422A0
(en)
|
2001-09-20 |
2004-06-01 |
Cornell Res Foundation Inc |
Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
|
|
US20050215472A1
(en)
*
|
2001-10-23 |
2005-09-29 |
Psma Development Company, Llc |
PSMA formulations and uses thereof
|
|
WO2003034903A2
(en)
*
|
2001-10-23 |
2003-05-01 |
Psma Development Company, L.L.C. |
Psma antibodies and protein multimers
|
|
ATE408712T1
(de)
|
2003-01-10 |
2008-10-15 |
Millennium Pharm Inc |
Verfahren zur bestimmung des wiederauftretens von prostata krebs
|
|
US7902338B2
(en)
|
2003-07-31 |
2011-03-08 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
|
EP1610818A4
(en)
*
|
2004-03-03 |
2007-09-19 |
Millennium Pharm Inc |
MODIFIED ANTIBODIES AGAINST A PROSTATE-SPECIFIC MEMBRANE-ANTIGEN AND USE THEREOF
|
|
WO2006086345A2
(en)
*
|
2005-02-07 |
2006-08-17 |
The Trustees Of Columbia University In The City Of New York |
Methods to treat or prevent hormone-resistant prostate cancer using sirna specific for protocadherin-pc, or other inhibitors of protocadherin-pc expression or activity
|
|
NZ556661A
(en)
*
|
2005-02-18 |
2010-10-29 |
Medarex Inc |
Human monoclonal antibodies to prostate specific membrance antigen (PSMA)
|
|
BRPI0607796A2
(pt)
*
|
2005-02-18 |
2009-06-13 |
Medarex Inc |
composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparação e uso do mesmo, e, composição farmacêutica
|
|
RU2450832C2
(ru)
*
|
2006-10-25 |
2012-05-20 |
Конинклейке Филипс Электроникс Н.В. |
Контрастные вещества для детекции рака предстательной железы
|
|
AU2008302345A1
(en)
*
|
2007-09-19 |
2009-03-26 |
Oncofluor, Inc. |
Method for imaging and treating organs and tissues
|
|
EP2326350B1
(en)
|
2008-09-08 |
2013-09-04 |
Psma Development Company, L.L.C. |
Compounds for killing psma-expressing, taxane-resistant cancer cells
|
|
EP3912643B8
(en)
|
2009-02-13 |
2023-08-23 |
Immunomedics, Inc. |
Immunoconjugates with an intracellularly-cleavable linkage
|
|
EP2398504B1
(en)
|
2009-02-17 |
2018-11-28 |
Cornell Research Foundation, Inc. |
Methods and kits for diagnosis of cancer and prediction of therapeutic value
|
|
EP3009455A1
(en)
|
2009-09-16 |
2016-04-20 |
Immunomedics Inc. |
Class i anti-cea antibodies and uses thereof
|
|
CA2782333C
(en)
|
2009-12-02 |
2019-06-04 |
Imaginab, Inc. |
J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
|
|
ES2978177T3
(es)
|
2009-12-02 |
2024-09-06 |
Immunomedics Inc |
Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer
|
|
US20130052194A1
(en)
|
2009-12-16 |
2013-02-28 |
The Trustees Of The University Of Pennsylvania |
Anti-prostate cancer antibodies and methods of detection and treatment of prostate cancer using the same
|
|
WO2012097070A1
(en)
*
|
2011-01-11 |
2012-07-19 |
The Board Of Trustees Of The Leland Stanford Junior University |
Mass dots: nanoparticle isotope tags
|
|
AU2012250924B2
(en)
|
2011-05-02 |
2017-05-25 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
|
JP6181059B2
(ja)
|
2011-10-25 |
2017-08-16 |
メモリアル スローン−ケタリング キャンサー センター |
前立腺がんのための診断薬、予後判定薬、および治療薬としてのフリーｐｓａ抗体
|
|
US10441561B2
(en)
|
2012-07-26 |
2019-10-15 |
The William M. Yanbrough Foundation |
Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
|
|
AU2013302696B9
(en)
|
2012-08-14 |
2018-08-09 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
|
SI2900277T1
(sl)
|
2012-12-13 |
2022-05-31 |
Immunomedics, Inc. |
Odmerki imunokonjugatov protiteles in SN-38 za boljšo učinkovitost in zmanjšano toksičnost
|
|
US11109846B2
(en)
*
|
2014-02-14 |
2021-09-07 |
Memorial Sloan-Kettering Cancer Center |
System and method for providing assessment of tumor and other biological components contained in tissue biopsy samples
|
|
WO2015126548A1
(en)
|
2014-02-21 |
2015-08-27 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to trop-2 expressing cells
|
|
US9139649B2
(en)
|
2014-02-25 |
2015-09-22 |
Immunomedics, Inc. |
Humanized anti-CD22 antibody
|
|
WO2015200260A1
(en)
|
2014-06-24 |
2015-12-30 |
Immunomedics, Inc. |
Anti-histone therapy for vascular necrosis in severe glomerulonephritis
|
|
CN117138060A
(zh)
|
2014-10-07 |
2023-12-01 |
免疫医疗公司 |
抗体-药物缀合物的新辅助剂用途
|
|
WO2016172427A1
(en)
|
2015-04-22 |
2016-10-27 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
|
|
EA201792573A1
(ru)
|
2015-05-21 |
2018-04-30 |
Харпун Терапьютикс, Инк. |
Триспецифические связанные белки и способы их применения
|
|
EP4257134A3
(en)
|
2015-06-25 |
2024-01-24 |
Immunomedics, Inc. |
Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
PL3316885T3
(pl)
|
2015-07-01 |
2021-12-06 |
Immunomedics, Inc. |
Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a
|
|
WO2017027325A1
(en)
|
2015-08-07 |
2017-02-16 |
Imaginab, Inc. |
Antigen binding constructs to target molecules
|
|
CN116987189A
(zh)
|
2016-05-20 |
2023-11-03 |
哈普恩治疗公司 |
单链可变片段cd3结合蛋白质
|
|
JP7101621B2
(ja)
|
2016-05-20 |
2022-07-15 |
ハープーン セラピューティクス，インク． |
単一ドメイン血清アルブミン結合タンパク質
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
CN110198955A
(zh)
|
2016-11-23 |
2019-09-03 |
哈普恩治疗公司 |
前列腺特异性膜抗原结合蛋白质
|
|
EP3544629A4
(en)
|
2016-11-23 |
2020-06-17 |
Harpoon Therapeutics, Inc. |
PSMA TO BE TRISPECIFIC PROTEINS AND METHOD FOR USE THEREOF
|
|
WO2018147960A1
(en)
|
2017-02-08 |
2018-08-16 |
Imaginab, Inc. |
Extension sequences for diabodies
|
|
EP3589662A4
(en)
|
2017-02-28 |
2020-12-30 |
Harpoon Therapeutics, Inc. |
INDUCTIBLE MONOVALENT ANTIGEN BINDING PROTEIN
|
|
WO2018209304A1
(en)
|
2017-05-12 |
2018-11-15 |
Harpoon Therapeutics, Inc. |
Msln targeting trispecific proteins and methods of use
|
|
AU2018265856B2
(en)
*
|
2017-05-12 |
2023-04-27 |
Harpoon Therapeutics, Inc. |
Mesothelin binding proteins
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
HRP20241268T1
(hr)
|
2017-10-13 |
2024-12-06 |
Harpoon Therapeutics, Inc. |
Trispecifični proteini i postupci primjene
|
|
KR20210020903A
(ko)
|
2018-05-14 |
2021-02-24 |
하푼 테라퓨틱스, 인크. |
면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티
|
|
WO2020061482A1
(en)
|
2018-09-21 |
2020-03-26 |
Harpoon Therapeutics, Inc. |
Egfr binding proteins and methods of use
|
|
SG11202103022WA
(en)
|
2018-09-25 |
2021-04-29 |
Harpoon Therapeutics Inc |
Dll3 binding proteins and methods of use
|
|
US12516128B2
(en)
|
2019-05-14 |
2026-01-06 |
Harpoon Therapeutics, Inc. |
EpCAM binding proteins and methods of use
|
|
CA3170833A1
(en)
|
2020-02-21 |
2021-08-26 |
Harpoon Therapeutics, Inc. |
Flt3 binding proteins and methods of use
|
|
RU2757641C1
(ru)
*
|
2021-03-09 |
2021-10-19 |
Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) |
Способ лучевой терапии больных раком предстательной железы с метастазами в регионарных лимфатических узлах таза
|
|
US20250073349A1
(en)
|
2021-05-10 |
2025-03-06 |
Kawasaki Institute Of Industrial Promotion |
Antibody having reduced binding affinity for antigen
|